Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) CEO David P. Meeker sold 4,278 shares of the company's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total value of $254,241.54. Following the sale, the chief executive officer now directly owns 189,927 shares of the company's stock, valued at $11,287,361.61. The trade was a 2.20 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Rhythm Pharmaceuticals Price Performance
RYTM stock traded down $0.83 during trading on Friday, reaching $59.18. 372,997 shares of the company were exchanged, compared to its average volume of 477,675. The company has a market capitalization of $3.64 billion, a price-to-earnings ratio of -13.67 and a beta of 2.14. The company has a 50-day moving average of $57.26 and a two-hundred day moving average of $53.30. Rhythm Pharmaceuticals, Inc. has a twelve month low of $35.17 and a twelve month high of $68.58.
Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.07. The business had revenue of $33.20 million for the quarter, compared to the consensus estimate of $32.52 million. Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The firm's revenue was up 47.6% compared to the same quarter last year. During the same period last year, the company earned ($0.76) EPS. On average, analysts forecast that Rhythm Pharmaceuticals, Inc. will post -4.33 EPS for the current year.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $69.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Monday, December 23rd. The Goldman Sachs Group increased their price objective on Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the stock a "buy" rating in a research note on Thursday, December 5th. Needham & Company LLC boosted their target price on shares of Rhythm Pharmaceuticals from $55.00 to $64.00 and gave the company a "buy" rating in a research note on Wednesday, November 6th. Oppenheimer started coverage on shares of Rhythm Pharmaceuticals in a research report on Friday, December 20th. They set an "outperform" rating and a $76.00 target price for the company. Finally, TD Cowen lifted their target price on shares of Rhythm Pharmaceuticals from $55.00 to $65.00 and gave the company a "buy" rating in a research note on Wednesday, November 6th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $68.09.
Check Out Our Latest Stock Report on Rhythm Pharmaceuticals
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of RYTM. SRS Capital Advisors Inc. lifted its stake in shares of Rhythm Pharmaceuticals by 740.7% in the fourth quarter. SRS Capital Advisors Inc. now owns 454 shares of the company's stock worth $25,000 after acquiring an additional 400 shares during the period. Raleigh Capital Management Inc. bought a new position in Rhythm Pharmaceuticals during the 4th quarter worth approximately $28,000. SBI Securities Co. Ltd. bought a new stake in shares of Rhythm Pharmaceuticals in the 4th quarter valued at $37,000. R Squared Ltd acquired a new stake in shares of Rhythm Pharmaceuticals during the fourth quarter worth $44,000. Finally, ORG Wealth Partners LLC bought a new position in Rhythm Pharmaceuticals during the third quarter worth $63,000.
Rhythm Pharmaceuticals Company Profile
(
Get Free Report)
Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
Further Reading
Before you consider Rhythm Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.
While Rhythm Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
